Cell Therapy for Melanoma Resistant to Checkpoint Inhibitors
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new treatment called tumor infiltrating lymphocyte (TIL) therapy for melanoma that hasn't responded to standard immunotherapy drugs. The therapy involves taking immune cells from your tumor, growing more of them in the lab, and putting them back into your body to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old with good overall health and life expectancy greater than 6 months
- Advanced melanoma (unresectable or spread to other parts of body) confirmed by biopsy
- At least one accessible tumor lesion at least 1.5 cm in size that can be surgically removed
- Previous treatment with at least one anti-PD1 immunotherapy drug (like nivolumab or pembrolizumab) that did not work well enough
- No untreated brain tumors; previously treated brain tumors must be stable for at least 60 days
- Not currently taking high-dose steroids or other strong immune-suppressing medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This trial tests a personalized cell therapy using your own immune cells (tumor-infiltrating lymphocytes, or TILs) to fight advanced melanoma that has stopped responding to standard treatments like anti-PD-1 (immunotherapy). If you qualify, you'd receive your own TILs instead of chemotherapy.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.